Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas MacDonald

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Scientific Reports|December 15, 2015
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeysEric J Smith, Kara Olson, Lauric J Haber, et al.
Molecular Cancer Therapeutics|March 18, 2014
ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer modelsLi Zhang, Carla Castanaro, Bo Luan, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's DiseaseJohn Wityak, Michael E Prime, Frederick A Brookfield, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2019
A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor ModelsJohn O DaSilva, Katie Yang, Andres E Perez Bay, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's DiseaseMichael E Prime, Frederick A Brookfield, Stephen M Courtney, et al.
Plos One|March 27, 2019
Meso scale discovery-based assays for the detection of aggregated huntingtinWolfgang Reindl, Barbara Baldo, Jana Schulz, et al.
Scientific Reports|July 13, 2017
Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease modelsManuel Daldin, Valentina Fodale, Cristina Cariulo, et al.
Cytotherapy|December 9, 2025
Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell linesJonida Kokiçi, Helena Arellano-Ballestero, Benjamin Hammond, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell linesJonida Kokiçi, Helena Arellano-Ballestero, Benjamin Hammond, et al.
Science Immunology|November 4, 2018
<b>Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8</b>Bei Wang, Wen Zhang, Vladimir Jankovic, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Scientific Reports|December 15, 2015
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeysEric J Smith, Kara Olson, Lauric J Haber, et al.
Molecular Cancer Therapeutics|March 18, 2014
ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer modelsLi Zhang, Carla Castanaro, Bo Luan, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's DiseaseJohn Wityak, Michael E Prime, Frederick A Brookfield, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2019
A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor ModelsJohn O DaSilva, Katie Yang, Andres E Perez Bay, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's DiseaseMichael E Prime, Frederick A Brookfield, Stephen M Courtney, et al.
Plos One|March 27, 2019
Meso scale discovery-based assays for the detection of aggregated huntingtinWolfgang Reindl, Barbara Baldo, Jana Schulz, et al.
Scientific Reports|July 13, 2017
Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease modelsManuel Daldin, Valentina Fodale, Cristina Cariulo, et al.
Cytotherapy|December 9, 2025
Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell linesJonida Kokiçi, Helena Arellano-Ballestero, Benjamin Hammond, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell linesJonida Kokiçi, Helena Arellano-Ballestero, Benjamin Hammond, et al.
Science Immunology|November 4, 2018
<b>Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8</b>Bei Wang, Wen Zhang, Vladimir Jankovic, et al.
Pageof 9